Daol Investment & Securities expects strong Q4 performance for APR, citing growth in North American sales
Kim SangJin
letyou@alphabiz.co.kr | 2024-12-05 08:05:24
[Alpha Biz= Reporter Kim Sangjin] Daol Investment & Securities issued a "Buy" rating and a target price of 80,000 KRW for APR on December 5, anticipating a strong Q4 performance driven by growth in North American sales.
The firm explained, "Based on Google Trends and Amazon bestseller rankings during Black Friday, we expect APR’s North American sales to perform well in Q4. The MediCube brand surpassed K-beauty indie brands COSRX and Chosun Beauty in Google Trends."
Additionally, Daol noted that APR’s main product, BoosterPro, maintains its position as the top product in the anti-aging device category, while BoosterHealer ranks between second and fourth. In the cosmetics toner category, Zero Pore Pad holds the top spot.
Daol forecasted that APR’s Q4 sales will increase by 40% year-on-year to 212.9 billion KRW, with operating profit rising 13% to 39 billion KRW. Particularly, North American sales are expected to show a 100% year-on-year increase, reaching 59.8 billion KRW.
The firm concluded, "In the short term, expanding B2B retailer contracts in key markets and entering non-core markets will be effective. In the mid-to-long term, we expect APR to become a leading player in the anti-aging sector through the expansion of its medical device business."
[ⓒ AlphaBIZ. 무단전재-재배포 금지]
많이 본 기사
- 1AMD’s Lisa Su Forges Broad Semiconductor Alliance with Samsung Electronics and Naver in Korea
- 2Trial to Begin in NPS Lawsuit Against Samsung Over 2015 Merger
- 3SEC Reclassifies Major Cryptocurrencies as Digital Commodities, Signaling Regulatory Shift
- 4Kyobo Life Enters Savings Bank Sector After Securing Approval to Acquire SBI Savings Bank
- 5LPG Shortage Deepens in India Amid Hormuz Disruption, Triggering Theft and Cooking Fuel Shift
- 6Korea Exchange Pledges Process Overhaul and Accountability After SCM Life Science Listing Error